natureresearch

Double-blind peer review submissions: write DBPR and your manuscript number here

Corresponding author(s): instead of author names.

Last updated by author(s): YYYY-MM-DD

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

Statistics					
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed					
The exact sam	pple size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.				
A description	X A description of all covariates tested				
A description	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
 X	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hypot	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
For Bayesian a	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierarchic	al and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estimates of e	effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated				
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and c	ode:				
Policy information abou	ut availability of computer code				
Data collection	N/A				
Data analysis	Statistical analysis was performed using the StatView 5.0 software.				
	om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.				
Data					
- Accession codes, un - A list of figures that	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability				
Source data are provided	as a Source Data file.				
Field-speci	fic reporting				
Please select the one b	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of the do	ocument with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				

ı • C	•			
Lite	sciences	stud	y c	lesign

Lite scien	ces sti	uay aesign		
All studies must disc	lose on these	points even when the disclosure is negative.		
Sample size	We did not determine sample size statistically, but the sample size for each group typical for this type of work in literature was chosen.			
Data exclusions	No data were excluded from the analysis.			
Replication	All attempts at replication were successful.			
Randomization	Randomization was used whenever possible.			
Blinding	Investigators w	ere not blinded to allocation during experiments and outcome assessment.		
Dillianig		are not surface to discussion daming experiments and cutoome assessment.		
_				
Reporting	g for sp	pecific materials, systems and methods		
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	erimental s	ystems Methods		
n/a Involved in the	study	n/a Involved in the study		
Antibodies		ChIP-seq		
x Eukaryotic c		Flow cytometry		
× Palaeontolog		MRI-based neuroimaging		
	other organism			
Clinical data	arch participant	.s		
Cirrical data				
Antibodies				
Antibodies used	p-	IRb: CST #3024, t-IRb: CST #3025, p-Akt: CST #9271, t-Akt: CST #9272, IRS1: Santa Cruz #sc-559, IRS2: Santa Cruz #sc-1555,		
GA		APDH: CST #2118, gH2AX: CST #9718, H3K9me3: CST #13696, H3K9me2: Active Motif #39240, Ki67: Nichirei #418071, IL1a-PE:		
		iltenyi Biotec #130-104-481, REA Control (I)-PE: Miltenyi Biotec #130-104-613, 8-OHdG: Japan Institute for the Control of Aging MOG-020P		
Validation According to		ecording to the data sheet, all the antibodies used for immunoblotting can detect target proteins. Also, 8-OHdG antibody is		
validation		itable for immunohistchemistry according to the data sheet.		
Eukaryotic ce	ell lines			
Policy information al	bout <u>cell lines</u>			
Cell line source(s)		We used 3T3-L1 preadipocytes, and C2C12 myoblasts.		
Authentication		3T3-L1 preadipocytes were provided by the cell bank of National Institutes of Biomedical Innovation, Health and Nutrition. C2C12 myoblasts were obtained from the ATCC.		
Mycoplasma conta	amination	Culture cells were regularly tested for mycoplasma contamination. We have confirmed the negative results for the cells used		
		in our experiments.		
Commonly misider (See ICLAC register)	ntified lines	N/A		
(See <u>repre</u> register)				
Animals and	other org	ganisms		
		nvolving animals; ARRIVE guidelines recommended for reporting animal research		
Laboratory animal	s W	de have reported necessary information appropriately in the manuscript.		
Wild animals	(N,	/A		
Field-collected san	nples N	/A		

Ethics oversight

All animal experimental protocols were approved by the Ethics Review Committee for Animal Experimentation of Kobe Pharmaceutical University.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

-low Cytometry				
Plots				
Confirm that:				
The axis labels state the m	narker and fluorochrome used (e.g. CD4-FITC).			
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).				
All plots are contour plots	s with outliers or pseudocolor plots.			
🗶 A numerical value for nun	nber of cells or percentage (with statistics) is provided.			
Methodology				
Sample preparation	$\begin{tabular}{ll} Endothelial cells were isolated from mouse lungs using MACS system (Miltenyi Biotec) according to the manufacturers protocols and the manufacturers of the $			
Instrument	FACSCalibur (BD Bioscience) was used for data collection.			
Software	FlowJo software (Tree Star) was used to collect and analyze the data.			
Cell population abundance	Successful endothelial cell isolation was confirmed by their abundant EC-markers expression as shown in the Supplementary Figure 6a.			
Gating strategy	We described the gating strategy in the Supplementary Methods.			

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.